Press release
Sideline RSV
A new health education campaign aimed to bring the conversation around the potential seriousness of Respiratory Syncytial Virus (RSV) center court for older adults.
GSK’s Dr. Len Friedland, VP and Director of Scientific Affairs and Public Health for Sideline RSV
Investors
We have announced our full year and Q4 2022 Results
Press releases
- GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
- US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate
- Landmark New England Journal of Medicine publication reinforces potential of GSK’s respiratory syncytial virus older adult vaccine candidate


Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSKUS on twitter
GSK Global links
Visit our Global site for additional features